Who
Anand Mehra
Director
Company insider
Files Form 4 as: Director and 10% owner, Aclaris Therapeutics; Director, Merus; Director, Spark Therapeutics; 10% owner, Principia Biopharma; Director and 10% owner, Marinus Pharmaceuticals; 10% owner, aTyr Pharma; Director and 10% owner, Aerie Pharmaceuticals; 10% owner, Alimera Sciences.
In numbers
- Trades disclosed
- 173
- Buys
- 7
- Sells
- 40
- Bought
- $27.1M
- Sold
- $171.4M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 25 Oct 2013
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,580 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,580 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,350 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,987 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —13,193 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,844 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —14,414 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —16,604 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —6,120 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,631 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —17,000 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —5,650 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —4,983 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | Merusoption or derivative | SEC FORM 4 Code D | —8,500 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,793 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | ACRS Aclaris TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,793 | filing |
News
No headline names them, or the companies they trade most, lately.